Free Trial

7 Stagflation Stocks to Help Navigate Periods of Low Growth - 4 of 7

 
 

#4 - Johnson & Johnson (NYSE:JNJ)

The final defensive stock on this list is Johnson & Johnson (NYSE:JNJ). As with many sectors, there are several attractive options in the pharmaceutical space. Some people may prefer Pfizer (NYSE:PFE), I’ll give the nod to JNJ because it offers exposure to both the pharmaceutical and consumer essentials space.

But that’s also why JNJ may not be a long-term play. The stock is showing tepid growth this year after the company announced it was going to spin off its consumer products division into a separate company. This is projected to happen in 2023. However, in the meantime, the company continues to generate consistent FCF that was $19.75 billion in 2021, down just a shade from the over $20 billion it generated in 2021.

And that growth is reflected in the company’s dividend which Johnson & Johnson just increased for the 61st consecutive year. This will keep JNJ in the exclusive group of stocks known as Dividend Kings.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Read More 
Current Price
$144.47
Consensus Rating
Moderate Buy
Ratings Breakdown
7 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$174.73 (20.9% Upside)

 

Cackling Kamala hates this company (Ad)

Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.

Before that happens, you need to see the details here.